title: Estimation of Cancer Burden Attributable to Infection in Asia.
abstract: BACKGROUND
  Some infectious agents have been shown to be human carcinogens. The current study focused on estimation of cancer burden attributable to infection in different regions of Asia.
  
  
  METHODS
  By systematically reviewing previous studies of the infection prevalence data of 13 countries in Asia and relative risks of specific cancers, we calculated the population attributable fraction of carcinogenic infections. Using data from GLOBOCAN 2012, the overall country-specific and gender-specific number of new cancer cases and deaths resulting from infection were estimated.
  
  
  RESULTS
  Across 13 principal Asian countries, the average prevalence and range was 6.6% (0.5% in Japanese women to 15.0% in Vietnamese men) for hepatitis B virus (HBV), 2.6% (0.3% in Iran to 5.1% in Saudi Arabia) for hepatitis C virus (HCV), 7.9% (2.8% in Pakistan to 17.7% in China) for human papillomavirus (HPV), and 61.8% (12.8% in Indonesia to 91.7% in Bangladesh) for Helicobacter pylori (HP). The estimated total number of cancer cases and deaths caused by infection in these 13 countries were 1 212 026 (19.6% of all new cancer cases) and 908 549 (22.0% of all deaths from cancer). The fractions of cancer incidence attributable to infection were 19.7% and 19.5% in men and women, respectively. The percentages of cancer deaths attributable to infection were 21.9% and 22.1% in men and women, respectively. Among the main infectious agents, HP was responsible for 31.5% of infection-related cancer cases and 32.8% of infection-related cancer deaths, followed by HBV (28.6% of new cases and 23.8% of deaths), HPV (22.0% of new cases and 27.3% of deaths), and HCV (12.2% of new cases and 10.6% of deaths).
  
  
  CONCLUSIONS
  Approximately one quarter of all cancer cases and deaths were infection-associated in Asia, which could be effectively prevented if appropriate long-term controls of infectious agents were applied.
authors.affiliation: Department of Cancer Epidemiology, Cancer Institute, Chinese Academy of Medical Sciences & Peking Union Medical College.
authors.forename: He
authors.initials: H
authors.lastname: Huang
authors.forename: Xiao-Feng
authors.initials: XF
authors.lastname: Hu
authors.forename: Fang-Hui
authors.initials: FH
authors.lastname: Zhao
authors.forename: Suzanne M
authors.initials: SM
authors.lastname: Garland
authors.forename: Neerja
authors.initials: N
authors.lastname: Bhatla
authors.forename: You-Lin
authors.initials: YL
authors.lastname: Qiao
mesh_terms: D001208:Asia / Q000453:epidemiology; D002423:Cause of Death / Q000639:trends; D017281:Cost of Illness; D005260:Female; D016481:Helicobacter Infections / Q000150:complications / Q000453:epidemiology; D006509:Hepatitis B / Q000150:complications / Q000453:epidemiology; D006526:Hepatitis C / Q000150:complications / Q000453:epidemiology; D006801:Humans; D007239:Infections / Q000150:complications* / Q000453:epidemiology; D008297:Male; D009369:Neoplasms / Q000453:epidemiology / Q000382:microbiology* / Q000821:virology*; D030361:Papillomavirus Infections / Q000150:complications / Q000453:epidemiology; D018570:Risk Assessment